COCP - Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK
- Cocrystal Pharma ( NASDAQ: COCP ) said it has engaged Open Orphan's ( OTCPK:OPORF ) unit hVIVO to conduct a phase 2a trial of its oral antiviral CC-42344 to treat pandemic and seasonal influenza A, in the U.K.
- The trial is expected to begin in H2 2023, pending regulatory approval in the U.K.
- "We are highly encouraged by the Phase 1 healthy volunteer trial results received so far and are committed to rapidly advancing this program into a human challenge Phase 2a trial in influenza A-infected subjects," said Cocrystal's President and Co-Interim CEO Sam Lee.
- Cocrystal is conducting a phase 1 trial of CC-42344 in healthy people in Australia, with full study results expected in 2022.
For further details see:
Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK